Scantox continues its growth journey with the acquisition of Solural Pharma
Scantox A/S (“Scantox”) announces the acquisition of Solural Pharma (“Solural”) in Denmark. Scantox is the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo.
Solural has strong expertise in all aspects of formulation development, GMP manufacturing and packaging to support phase 1 & 2 clinical trials. Solural develops formulations, from concept idea to clinical proof of concept. The company’s formulation technology platform provides innovative oral and topical products having unique benefits regarding efficacy, safety and convenience thereby meeting the needs from patients, doctors and society alike for the treatment of important medical conditions.
Jeanet Løgsted, CEO of Scantox: “The acquisition of Solural will enable Scantox to meet customer demand with suitable formulation development from lead optimization through to phase 2 clinical trials. Further to our recent investments in bioanalysis, we are focused on meeting the current and future market requirements, leading to even shorter timelines to our customers, and cement our position as a preferred service provider and partner to our expanding portfolio of customers within pharma, biotech, and medical device companies.”
Ann Fullerton, COO of Solural: “We are looking forward to leveraging the synergies across Scantox to deliver the best customized solutions to the market. Our expertise in oral and topical formulation development and manufacturing for both pre-clinical and clinical trials will fit very well into the Scantox portfolio, and I am convinced that current and new customers will benefit from the full service offering for their pre-clinical and clinical development requirements.”
Solural will be integrated and operate under the Scantox name.
Nicholas Hooge, Partner at Impilo, concludes: “With the acquisition of Solural, Scantox has taken another important step in the execution of the company’s long-term growth strategy. Impilo looks forward to continuing working with Scantox to further expand its portfolio of services and to strengthen its position globally and remains excited about the future potential in the sector.”
With this acquisition Scantox has over 200 employees across five sites.
For further information, please contact:
Jeanet Løgsted, CEO of Scantox, +45 56861500, jln@scantox.com
Ann Fullerton, MD and COO of Solural Pharma, +45 2566 7575, afu@soluralpharma.com
Jeanet Løgsted, CEO Scantox Group
Tags:
